Expression of paxillin is correlated with clinical prognosis in colorectal cancer patients

Medical Science Monitor

Volumn 21, Issue , 2015, Pages 1989-1995

  Zhao, Cheng Jin ^a   Du, Shuang Kuan ^a   Dang, Xing Bo ^a   Gong, Min ^b  

^a SHAANXI PROVINCIAL PEOPLE S HOSPITAL   (China)

^b UNION HOSPITAL   (China)

Author keywords

Colorectal Neoplasms; Paxillin; Prognosis

Indexed keywords

GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; PAXILLIN; TUMOR MARKER;

ADULT; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; COLORECTAL CANCER; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; ONCOLOGICAL PARAMETERS; PROTEIN EXPRESSION; RADICAL RESECTION; REAL TIME POLYMERASE CHAIN REACTION; STAINING; TUMOR VOLUME; COLORECTAL NEOPLASMS; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; PAXILLIN; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84937140592     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.893832     Document Type: Article

References (32)

1. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. Cancer J Clin, 2010; 60: 277–300
2. O’Neil BH, Goldberg RM: Innovations in chemotherapy for metastatic colorec-tal cancer: an update of recent clinical trials. Oncologist, 2008; 13: 1074–83
3. Wang CC, Li J: An update on chemotherapy of colorectal liver metastases. World J Gastroenterol, 2012; 18: 25–33
4. Singla A, Broadbridge V, Mittinty M et al: Rural populations have equal surgical and survival outcomes in metastatic colorectal cancer. Aust J Rural Health, 2014; 22: 249–56
5. Gupta GP, Massagué J: Cancer metastasis: building a framework. Cell, 2006; 127: 679–95
6. Schaller MD: Paxillin: a focal adhesion-associated adaptor protein. Oncogene, 2001; 20: 6459–72
7. Turner CE: Paxillin and focal adhesion signalling. Nat Cell Biol, 2000; 2: E231–36
8. Hammes SR, Miedlich SU, Sen A: Paxillin and steroid signaling: from frog to human. Methods Mol Biol, 2014; 1204: 95–108
9. Kasai M, Guerrero-Santoro J, Friedman R et al: The Group 3 LIM domain protein Paxillin potentiates androgen receptor transactivation in prostate cancer cell lines. Cancer Res, 2003; 63: 4927–35
10. Brown MC, Cary LA, Jamieson JS et al: Src and FAK kinases cooperate to phosphorylate Paxillin kinase linker, stimulate its focal adhesion localization, and regulate cell spreading and protrusiveness. Mol Biol Cell, 2005; 16: 4316–28
11. Brimer N, Wade R, Vande Pol S: Interactions between E6, FAK, and GIT1 at Paxillin LD4 are necessary for transformation by bovine papillomavirus 1 E6. J Virol, 2014; 88: 9927–33
12. Cheng K, Kurzrock R, Qiu X et al: Reduced focal adhesion kinase and Paxillin phosphorylation in BCR-ABL-transfected cells. Cancer, 2002; 95: 440–50
13. Salgia R, Li JL, Ewaniuk DS et al: Expression of the focal adhesion protein Paxillin in lung cancer and its relation to cell motility. Oncogene, 1999; 18: 67–77
14. Kawada I, Hasina R, Lennon FE et al: Paxillin mutations afect focal adhesions and lead to altered mitochondrial dynamics: relevance to lung cancer. Cancer Biol Ther, 2013; 14: 679–91
15. Li D, Ding J, Wang X et al: Fibronectin promotes tyrosine phosphorylation of Paxillin and cell invasiveness in the gastric cancer cell line AGS. Tumori, 2009; 95: 769–79
16. Liu CJ, Kuo FC, Hu HM et al: 17b-Estradiol inhibition of IL-6-Src and Cas and Paxillin pathway suppresses human mesenchymal stem cells-mediated gastric cancer cell motility. Transl Res, 2014; 164: 232–43
17. Mackinnon AC, Tretiakova M, Henderson L et al: Paxillin expression and amplifcation in early lung lesions of high-risk patients, lung adenocarci-noma and metastatic disease. J Clin Pathol, 2011; 64: 16–24
18. Sen A, De Castro I, Defranco DB et al: Paxillin mediates extranuclear and intranuclear signaling in prostate cancer proliferation. J Clin Invest, 2012; 122: 2469–81
19. Shi J, Wang S, Zhao E et al: Paxillin expression levels are correlated with clinical stage and metastasis in salivary adenoid cystic carcinoma. J Oral Pathol Med, 2010; 39: 548–51
20. Li HG, Xie DR, Shen XM et al: Clinicopathological signifcance of expression of Paxillin, syndecan-1 and EMMPRIN in hepatocellular carcinoma. World J Gastroenterol, 2005; 11: 1445–51
21. Juliano RL: Signal transduction by cell adhesion receptors and the cytoskel-eton: functions of integrins, cadherins, selectins, and immunoglobulin-su-perfamily members. Annu Rev Pharmacol Toxicol, 2002; 42: 283–23
22. Giancotti FG, Tarone G: Positional control of cell fate through joint inte-grin/receptor protein kinase signaling. Annu Rev Cell Dev Biol, 2003; 19: 173–206
23. Calalb MB, Polte TR, Hanks SK: Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family kinases. Mol Cell Biol, 1995; 15: 954–63
24. Brown MC, Turner CE: Paxillin: adapting to change. Physiol Rev, 2004; 84: 1315–39
25. Mitra SK, Hanson DA, Schlaepfer DD: Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol, 2005; 6: 56–68
26. Vallés AM, Beuvin M, Boyer B: Activation of Rac1 by Paxillin-Crk-DOCK180 signaling complex is antagonized by Rap1 in migrating NBT-II cells. J Biol Chem, 2004; 279: 44490–96
27. Kratimenos P, Koutroulis I, Marconi D et al: Multi-targeted molecular therapeutic approach in aggressive neuroblastoma: the efect of Focal Adhesion Kinase-Src-Paxillin system. Expert Opin Ther Targets, 2014; 18(12): 1395–406
28. Avizienyte E, Brunton VG, Fincham VJ, Frame MC: The SRC-induced mesen-chymal state in late-stage colon cancer cells. Cells Tissues Organs, 2005; 179: 73–80
29. Jagadeeswaran R, Surawska H, Krishnaswamy S et al: Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. Cancer Res, 2008; 68: 132–42
30. Lee YC, Chang AY, Lin-Feng MH et al: Paxillin phosphorylation by JNK and p38 is required for NFAT activation. Eur J Immunol, 2012; 42: 2165–75
31. Chen HY, Shen CH, Tsai YT et al: Brk activates rac1 and promotes cell migration and invasion by phosphorylating Paxillin. Mol Cell Biol, 2004; 24: 10558–72
32. Downey C, Craig DH, Basson MD: Pressure activates colon cancer cell adhesion via Paxillin phosphorylation, Crk, Cas, and Rac1. Cell Mol Life Sci, 2008; 65: 1446–57